Signet Accel provides the collaborative healthcare analytics platform for clinical practice and biomedical and translational research. The Avec™ product is a distributed (decentralized) patient disease registry solution that enables each organization (hospitals, research centers, biopharma companies, CRO’s, etc.) to securely share and analyze data with authorized collaborators while maintaining full ownership and control over their own repositories. The technology was developed at The Ohio State University and has been successfully deployed in federated multi-site commercial projects. Signet Accel’s solution and services are designed to eliminate barriers and boundaries for collaboration and data utilization by unifying geographically separated systems and integrating silos of clinical and biomedical information, including EHR data, Biospecimen and clinical trials information, medical practice and quality improvement data, meaningful use reports, drug safety, translational research data, and population- and disease-specific data. Amperand principals participated in commercialization and formation of this rapidly growing company and developed the business plan.
Dr. Jeff Spitzner provided early “employee number 1” business and technology management for Signet Accel as its Chief Science Officer. Dr. Spitzner was a co-leader on the 2003 grant that funded the initial development of the technology at Ohio State (for Rescentris in a$6 Million Public-Private Partnership grant) . In 2012-13, Jeff built relationships with the OSU research leadership (inventors) and the OSU Technology Commercialization Office, identified this as ready to spin out, and brought in private equity firm Signet Enterprises as the investment group to fund the deal and form the company. Spitzner continues to identify and perform due diligence on potential future investments for Signet Innovations.